AN OPEN-LABEL, PHASE I/IIA STUDY OF VB10.NEO (DIRECT-01) IN COMBINATION WITH CHECKPOINT BLOCKADE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS INCLUDING MELANOMA, NSCLC, RENAL CELL CARCINOMA, UROTHELIAL CANCER OR SSCHN